Sphingosine Kinases as Druggable Targets

Susan Pyne, David Roger Adams, Nigel J. Pyne

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

Abstract

There is substantial evidence that the enzymes, sphingosine kinase 1 and 2, which catalyse the formation of the bioactive lipid sphingosine 1-phosphate, are involved in pathophysiological processes. In this chapter, we appraise the evidence that both enzymes are druggable and describe how isoform-specific inhibitors can be developed based on the plasticity of the sphingosine-binding site. This is contextualised with the effect of sphingosine kinase inhibitors in cancer, pulmonary hypertension, neurodegeneration, inflammation and sickling.

Original languageEnglish
Title of host publicationLipid Signaling in Human Diseases
PublisherSpringer
Pages49-76
Number of pages28
ISBN (Electronic)9783030336684
ISBN (Print)9783030336677
DOIs
Publication statusPublished - 2018

Publication series

NameHandbook of Experimental Pharmacology
Volume259
ISSN (Print)0171-2004
ISSN (Electronic)1865-0325

Fingerprint Dive into the research topics of 'Sphingosine Kinases as Druggable Targets'. Together they form a unique fingerprint.

  • Cite this

    Pyne, S., Adams, D. R., & Pyne, N. J. (2018). Sphingosine Kinases as Druggable Targets. In Lipid Signaling in Human Diseases (pp. 49-76). (Handbook of Experimental Pharmacology; Vol. 259). Springer. https://doi.org/10.1007/164_2018_96